Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Blood (2023) 142 (Supplement 1): 3166.

https://doi.org/10.1182/blood-2023-174455

Published: 2023

Journal Articles

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Gopila Gupta, May Chiu, Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Lucero, Daniela Zackova, Ivana Jeziskova, Anezka Kvetkova, Tomas Jurcek, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Jiri Mayer, Jessie Medeiros, Sagi Abelson, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4531.

https://doi.org/10.1182/blood-2023-189827

Published: 2023

Journal Articles

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Blood (2023) 142 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2023-189797

Published: 2023

Journal Articles

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Blood (2022) 140 (Supplement 1): 6774–6775.

https://doi.org/10.1182/blood-2022-168228

Published: 2022

Journal Articles

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Blood (2022) 140 (Supplement 1): 6782–6783.

https://doi.org/10.1182/blood-2022-167927

Published: 2022

Journal Articles

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Taehyung Kim, Daniela Žácková, Ivana Ježíšková, Anežka Kvetková, Tomáš Jurček, Young Seok Yoo, Hyewon Lee, Kyoung Ha Kim, Myung Hee Chang, Seong Yoon Yi, Jessie J.F. Medeiros, Sagi Abelson, Dennis Kim

Blood (2022) 140 (Supplement 1): 812–814.

https://doi.org/10.1182/blood-2022-162676

Published: 2022

Journal Articles

Palbociclib and Ponatinib Suppress Acute Myeloid Leukemia in Patient-Derived Xenograft

Daniel Busa, Tomas Loja, Ivana Jeziskova, Adam Folta, Jiri Mayer, Martin Culen

Blood (2021) 138 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2021-145972

Published: 2021

Journal Articles

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Blood (2021) 138 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2021-146221

Published: 2021

Journal Articles

Methscore As a New Prognostic Tool for Complex DNA Methylation Changes Assessment in Patients with Acute Myeloid Leukemia

Sarka Sestakova, Cyril Šálek, MD, Dávid Kundrát, Ivana Ježíšková, Jiří Mayer, Zdeněk Ráčil, Petr Cetkovský, Hana Remešová

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-137380

Published: 2020

Journal Articles

A Comparison of Two Standardized Quantitative RT-PCRs with CE IVD Kit for Digital PCR in CML Patients with Different Level of BCR-ABL1 Transcripts

Adam Folta, Tomas Jurcek, Blanka Kubesova, Daniela Zackova, Jiri Mayer, MD, Ivana Jeziskova

Blood (2019) 134 (Supplement_1): 1646.

https://doi.org/10.1182/blood-2019-125551

Published: 2019

Journal Articles

Persistence of Mutations during Remission in 114 AML Patients

Martin Culen, PhD, Zdenka Kosarova, MSc, Ivana Jeziskova, PhD, Adam Folta, PhD, Nikola Tom, MSc, Ondrej Venglár, Dana Dvorakova, PhD, Jiri Mayer, MD, Zdenek Racil

Blood (2018) 132 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2018-99-110586

Published: 2018

Journal Articles

Simulation of AML Clonality in Patient-Derived Xenografts

Zdenka Kosarova, MSc, Martin Culen, PhD, Ivana Jeziskova, PhD, Adam Folta, PhD, Veronika Janeckova, PhD, Jana Cerna, PhD, Tomas Loja, PhD, Nikola Tom, MSc, Lukas Semerad, MD, Zuzana Sustkova, MD, Dana Dvorakova, PhD, Jiri Mayer, Prof, MD SCs, Zdenek Racil, MD

Blood (2017) 130 (Supplement 1): 3915.

https://doi.org/10.1182/blood.V130.Suppl_1.3915.3915

Published: 2017

Journal Articles

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML) – a Single Center Experience in 27 Patients.

Dana Dvorakova, Zdenek Racil, Ivo Palasek, Marketa Protivankova, Ivana Jeziskova, Martina Lengerova, Jiri Mayer

Blood (2009) 114 (22): 4672.

https://doi.org/10.1182/blood.V114.22.4672.4672

Published: 2009

NARROW

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Palbociclib and Ponatinib Suppress Acute Myeloid Leukemia in Patient-Derived Xenograft

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Methscore As a New Prognostic Tool for Complex DNA Methylation Changes Assessment in Patients with Acute Myeloid Leukemia

A Comparison of Two Standardized Quantitative RT-PCRs with CE IVD Kit for Digital PCR in CML Patients with Different Level of BCR-ABL1 Transcripts

Persistence of Mutations during Remission in 114 AML Patients

Simulation of AML Clonality in Patient-Derived Xenografts

Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML) – a Single Center Experience in 27 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only